Brian Cheng
Stock Analyst at JP Morgan
(0.94)
# 3,523
Out of 4,814 analysts
64
Total ratings
30.77%
Success rate
-23.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $19.00 | - | 1 | Mar 27, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $22 → $15 | $6.45 | +132.56% | 3 | Mar 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $46.32 | +23.06% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $7.27 | +78.94% | 4 | Feb 28, 2025 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $126 → $129 | $84.69 | +52.32% | 2 | Feb 4, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.65 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.29 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $11.54 | +55.98% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $9.69 | +188.96% | 4 | Nov 7, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $15.15 | +203.73% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $1.85 | +1,688.62% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.52 | +296.04% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $7.92 | +203.22% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.40 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.35 | +1,310.04% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.45 | +451.72% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $10.14 | +47.93% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.32 | +4,246.48% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.23 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.53 | +1,041.12% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.83 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.84 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.04 | +880.39% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $10.51 | +708.75% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.39 | +184.17% | 1 | Aug 3, 2021 |
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $19.00
Upside: -
iTeos Therapeutics
Mar 6, 2025
Maintains: Overweight
Price Target: $22 → $15
Current: $6.45
Upside: +132.56%
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $46.32
Upside: +23.06%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $7.27
Upside: +78.94%
Blueprint Medicines
Feb 4, 2025
Maintains: Overweight
Price Target: $126 → $129
Current: $84.69
Upside: +52.32%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.65
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.29
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $11.54
Upside: +55.98%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $9.69
Upside: +188.96%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $15.15
Upside: +203.73%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $1.85
Upside: +1,688.62%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.52
Upside: +296.04%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $7.92
Upside: +203.22%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.40
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.35
Upside: +1,310.04%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.45
Upside: +451.72%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $10.14
Upside: +47.93%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.32
Upside: +4,246.48%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.53
Upside: +1,041.12%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.83
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.84
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $2.04
Upside: +880.39%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $10.51
Upside: +708.75%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.39
Upside: +184.17%